UNSPSC 51183509: Metformin glycinate

This classification denotes an anti-diabetic agent C4H11N5.C2H5NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YEI21W005Y, chemically known as glycine, compd. with n,n-dimethylimidodicarbonimidic diamide (1:1), but more generally known as metformin glycinate, which bears US NIH Compound Identifier 44520175. Most nations, for tariff and trade purposes, schedule metformin glycinate under HS 29252900 and SITC 51482. As of Q4 2014, METFORMIN GLYCINATE remains US FDA's Preferred Term for this commodity.

SMILES: CN(C)C(=N)NC(=N)N.C(C(=O)O)N.

UNSPSC 51183509 Metformin glycinate is a Commodity code covering a specific pharmaceutical active ingredient and formulation. State and local governments procure metformin glycinate as part of broader generic pharmaceutical supply agreements serving Medicaid programs, public health clinics, correctional facilities, and other government healthcare operations. The scope of work under this code encompasses manufacturers and authorized distributors supplying compliant pharmaceutical products with verified National Drug Codes (NDCs), documented cGMP certification, and Drug Supply Chain Security Act (DSCSA) compliance. Issuing bodies include state health departments, Medicaid agencies, and multistate cooperative purchasing organizations that establish master contracts with multiple pharmaceutical manufacturers and authorized wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary vehicle for coordinated procurement across participating states and local jurisdictions.

The Minnesota Department of Administration's Office of State Procurement, acting through MMCAP, posted an RFP (S1070000015802) on January 20, 2026 for generic multi-source pharmaceuticals and OTC products, with metformin glycinate among the requested formulary items. The solicitation targets manufacturers supplying through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with proposals due March 26, 2026. Award criteria weight price competitiveness at 75 percent, with 10 percent for fixed pricing, 5 percent each for administrative fee data format compliance, EDI capability, and acceptance of a 3 percent administrative fee. Products must be available in the marketplace by May 15, 2026, with awarded contracts effective July 1, 2026 through June 30, 2028 for incumbent responders and two years for new responders. Vendors must maintain commercial general liability insurance of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, with performance penalties of $200 to $1,500 per violation for late reporting, missed timelines, or improper class-of-trade denials.